Targeting lymphocyte co-stimulation: From bench to bedside

References

• June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell activation. Immunol Today. 1990; 11 6: 211–216.
   PubMedGoogle Scholar
• Ledbetter JA, Imboden JB, Schieven GL, Grosmaire LS, Rabinovitch PS, Lindsten T, Thompson CB, June CH. CD28 ligation in T-cell activation: Evidence for two signal transduction pathways. Blood. 1990; 75 7: 1531–1539.
   PubMed Web of Science ®Google Scholar
• Schwartz RH, Mueller DL, Jenkins MK, Quill H. T-cell clonal anergy. Cold Spring Harb Symp Quant Biol. 1989; 54 pt 2: 605–610.
   PubMedGoogle Scholar
• Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA. 1989; 86 4: 1333–1337.
   PubMed Web of Science ®Google Scholar
• Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB. Absence of B7-dependent responses in CD28-deficient mice. Immunity. 1994; 1 6: 501–508.
   PubMed Web of Science ®Google Scholar
• Damle NK, Linsley PS, Ledbetter JA. Direct helper T-cell-induced B-cell differentiation involves interaction between T-cell antigen CD28 and B-cell activation antigen B7. Eur J Immunol. 1991; 21 5: 1277–1282.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B-cell activation antigen B7. J Exp Med. 1991; 174 3: 561–569.
   PubMed Web of Science ®Google Scholar
• Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, Ledbetter JA, Linsley PS. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med. 1993; 177 1: 165–173.
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3 5: 541–547.
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995; 270 5238: 985–988.
   PubMed Web of Science ®Google Scholar
• Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol. 2006; 24 1: 65–97.
   PubMed Web of Science ®Google Scholar
• Butte MJ, Pena-Cruz V, Kim MJ, Freeman GJ, Sharpe AH. Interaction of human PD-L1 and B7-1. Mol Immunol. 2008; 45 13: 3567–3572.
   PubMed Web of Science ®Google Scholar
• Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000; 12 4: 431–440.
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science. 1992; 257 5071: 789–792.
   PubMed Web of Science ®Google Scholar
• Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei RQ, Gibson ML, Zheng XG, Myrdal S, Gordon D, Bailey T, Bolling SF, Thompson CB. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA. 1992; 89 22: 11102–11105.
   PubMed Web of Science ®Google Scholar
• Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest. 1995; 96 2: 987–993.
   PubMed Web of Science ®Google Scholar
• Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2. Eur J Immunol. 1996; 26 10: 2320–2328.
   PubMed Web of Science ®Google Scholar
• Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994; 265 5176: 1225–1227.
   PubMed Web of Science ®Google Scholar
• Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, Perrin PJ. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest. 1995; 96 5: 2195–2203.
   PubMed Web of Science ®Google Scholar
• Arima T, Rehman A, Hickey WF, Flye MW. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. J Immunol. 1996; 156 12: 4916–4924.
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995; 181 3: 1145–1155.
   PubMed Web of Science ®Google Scholar
• Perrin PJ, June CH, Maldonado JH, Ratts RB, Racke MK. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol. 1999; 163 3: 1704–1710.
   PubMed Web of Science ®Google Scholar
• Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobertm E, Anderson D, Cowan S, Price K, Naemura J, Emswiler J, Greene J, Turk LA, Bajorath J, Townsend R, Hagerty D, Linsley PS, Peach RJ. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transpl. 2005; 5 3: 443–453.
   PubMed Web of Science ®Google Scholar
• Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol. 2007; 34 11: 2204–2210.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S, Tindall E, Becker JC, Li T, Nuamah IF, Aranda R, Moreland LW. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52 8: 2263–2271.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005; 353 11: 1114–1123.
   PubMed Web of Science ®Google Scholar
• Genant HK, Peterfy CG, Westhovens R, Becker JC, Aranda R, Vratsanos G, Teng J, Kremer JM. Abatacept inhibits progression of structural damage in rheumatoid arthritis: Results from the long-term extension of the AIM trial. Ann Rheum Dis. 2008; 67 8: 1084–1089.
   PubMed Web of Science ®Google Scholar
• Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, Radjenovic A, English A, Tang H, Vratsanos G, O'Connor P, Firestein GS, Emery P. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: A histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis. 2009; 68 7: 1220–1227.
   PubMed Web of Science ®Google Scholar
• Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, Vratsanos G, Zhou Y, Moreland LW. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006; 33 11: 2162–2166.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH. Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008; 372 9636: 383–391.
   PubMed Web of Science ®Google Scholar
• Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999; 103 9: 1243–1252.
   PubMed Web of Science ®Google Scholar
• Mease P, Genovese MC, Ritchlin C, Wollenhaupt J, Tak PP, Kivitz A, Gladstein G, Bahary O, Kelly S, Teng J, Becker J-C, Gladman DAbatacept in psoriatic arthritis: Results of a phase II study Presented at the ACR/ARHP Annual Scientific Meeting 2009; Abstract 1260.
   Google Scholar
• Merrill JTB-V, Westhovens R, Chalmers A, D'Cruz D, Wallace D, Bae S, Sigal L, Becker J, Kelly S, Raghupathi K, Peng Y, Kinaszczuk M, Nash PThe efficacy and safety of abatacept in SLE: Results of a 12-month exploratory study Presented at the American College of Rheumatology Annual Scientific Meeting 2008; Abstract L15.
   Google Scholar
• Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev. 2009; 229 1: 307–321.
   PubMed Web of Science ®Google Scholar
• Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ. CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial. Neurology. 2008; 71 12: 917–924.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel J-F, Hanauer S, Targan S, Schreiber S, Bressler B, Raghupathi K, Aranda R, Luo AYA randomized placebo-controlled trial of abatacept for moderately-to-severely active ulcerative colitis Presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2009; Abstract 47.
   Google Scholar
• Smitten AL, Qi K, Franklin J, Askling J, Lacaille D. Hospitalized infections in the abatacept RA clinical development program: An epidemiological assessment with >10,000 person-years of exposure. Arthritis Rheum. 2008; 58 S786 Abstract 1674.
   Google Scholar
• Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008; 10 2: R45.
   PubMed Web of Science ®Google Scholar
• Smitten A, Simon T, Becker JC. Autoimmune adverse events in the abatacept RA clinical development program: A safety analysis with >10,000 person-years of exposure. Arthritis Rheum. 2008; 58 S786 Abstract 1673.
   Google Scholar
• Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, Drager R, Eibel H, Fischer B, Schaffer AA, Mages HW, Kroczek RA, Peter HH. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol. 2003; 4 3: 261–268.
   PubMed Web of Science ®Google Scholar
• Bauquet AT, Jin H, Paterson AM, Mitsdoerffer M, Ho IC, Sharpe AH, Kuchroo VK. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol. 2009; 10 2: 167–175.
   PubMed Web of Science ®Google Scholar
• Nurieva RI, Treuting P, Duong J, Flavell RA, Dong C. Inducible costimulator is essential for collagen-induced arthritis. J Clin Invest. 2003; 111 5: 701–706.
   PubMed Web of Science ®Google Scholar
• Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001; 409 6816: 97–101.
   PubMed Web of Science ®Google Scholar
• Rottman JB, Smith T, Tonra JR, Ganley K, Bloom T, Silva R, Pierce B, Gutierrez-Ramos JC, Ozkaynak E, Coyle AJ. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol. 2001; 2 7: 605–611.
   PubMed Web of Science ®Google Scholar
• Mesturini R, Nicola S, Chiocchetti A, Bernardone IS, Castelli L, Bensi T, Ferretti M, Comi C, Dong C, Rojo JM, Yagi J, Dianzani U. ICOS cooperates with CD28, IL-2, and IFN-gamma and modulates activation of human naive CD4+ T cells. Eur J Immunol. 2006; 36 10: 2601–2612.
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006; 439 7077: 682–687.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999; 11 2: 141–151.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291 5502: 319–322.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Topalian S, Wollner I, Powderly JD, Picus J, Drake CG, Covino J, Korman A, Pardoll D, Lowy I. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol. 2008; 26 (May 20 suppl; abstr 3006).
   Web of Science ®Google Scholar
• Han P, Goularte OD, Rufner K, Wilkinson B, Kaye J. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol. 2004; 172 10: 5931–5939.
   PubMed Web of Science ®Google Scholar
• Hurchla MA, Sedy JR, Gavrieli M, Drake CG, Murphy TL, Murphy KM. B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+T cells. J Immunol. 2005; 174 6: 3377–3385.
   PubMed Web of Science ®Google Scholar
• Tao R, Wang L, Murphy KM, Fraser CC, Hancock WW. Regulatory T-cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol. 2008; 180 10: 6649–6655.
   PubMed Web of Science ®Google Scholar
• Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol. 2008; 9 2: 176–185.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+T-cell exhaustion during chronic viral infection. Immunity. 2007; 27 4: 670–684.
   PubMed Web of Science ®Google Scholar
• Abecassis S, Giustiniani J, Meyer N, Schiavon V, Ortonne N, Campillo JA, Bagot M, Bensussan A. Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: A possible role for CD160 in skin inflammation. J Invest Dermatol. 2007; 127 5: 1161–1166.
   PubMed Web of Science ®Google Scholar
• Oya Y, Watanabe N, Owada T, Oki M, Hirose K, Suto A, Kagami S, Nakajima H, Kishimoto T, Iwamoto I, Murphy TL, Murphy KM, Saito Y. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum. 2008; 58 8: 2498–2510.
   PubMedGoogle Scholar
• Tao R, Wang L, Han R, Wang T, Ye Q, Honjo T, Murphy TL, Murphy KM, Hancock WW. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J Immunol. 2005; 175 9: 5774–5782.
   PubMed Web of Science ®Google Scholar
• Truong W, Plester JC, Hancock WW, Merani S, Murphy TL, Murphy KM, Kaye J, Anderson CC, Shapiro AM. Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts. Am J Transpl. 2007; 7 12: 2663–2674.
   PubMed Web of Science ®Google Scholar
• Steinberg MW, Turovskaya O, Shaikh RB, Kim G, McCole DF, Pfeffer K, Murphy KM, Ware CF, Kronenberg M. A crucial role for HVEM and BTLA in preventing intestinal inflammation. J Exp Med. 2008; 205 6: 1463–1476.
   PubMed Web of Science ®Google Scholar
• Hurchla MA, Sedy JR, Murphy KM. Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimulation. J Immunol. 2007; 178 10: 6073–6082.
   PubMed Web of Science ®Google Scholar
• Truong W, Hancock WW, Plester JC, Merani S, Rayner DC, Thangavelu G, Murphy KM, Anderson CC, Shapiro AM. BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J Leukoc Biol. 2009; 86 1: 41–51.
   PubMed Web of Science ®Google Scholar
• Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: Crucial controls of immune tolerance and function. Immunol Rev. 2009; 229 1: 88–100.
   PubMedGoogle Scholar
• Lougaris V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: Clinical, molecular, and immunological features. Immunol Rev. 2005; 203:48–66.
   PubMed Web of Science ®Google Scholar
• Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, Bedell MA, Edelhoff S, Disteche CM, Simoneaux DK, Fanslow WC, Belmont J, Spriggs MK. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993; 259 5097: 990–993.
   PubMed Web of Science ®Google Scholar
• Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Bajorath J, Grosmaire LS, Stenkamp R, Neubauer M, Roberts RL, Noelle RJ, Ledbetter JA, Francke U, Ochs HD. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993; 72 2: 291–300.
   PubMed Web of Science ®Google Scholar
• Conley ME. An evolving view of hyper-IgM syndrome. J Pediatr. 1997; 131 1 Pt 1: 8–9.
   PubMed Web of Science ®Google Scholar
• DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature. 1993; 361 6412: 541–543.
   PubMed Web of Science ®Google Scholar
• Durandy A, Hivroz C, Mazerolles F, Schiff C, Bernard F, Jouanguy E, Revy P, DiSanto JP, Gauchat JF, Bonnefoy JY, Casanova JL, Fischer A. Abnormal CD40-mediated activation pathway in B lymphocytes from patients with hyper-IgM syndrome and normal CD40 ligand expression. J Immunol. 1997; 158 6: 2576–2584.
   PubMed Web of Science ®Google Scholar
• Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 1993; 361 6412: 539–541.
   PubMed Web of Science ®Google Scholar
• Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature. 1995; 378 6557: 617–620.
   PubMed Web of Science ®Google Scholar
• Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H. The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation. Immunity. 1994; 1 3: 167–178.
   PubMed Web of Science ®Google Scholar
• Xu J, Foy TM, Laman JD, Elliott EA, Dunn JJ, Waldschmidt TJ, Elsemore J, Noelle RJ, Flavell RA. Mice deficient for the CD40 ligand. Immunity. 1994; 1 5: 423–431.
   PubMed Web of Science ®Google Scholar
• Orozco G, Eyre S, Hinks A, Ke X, Wilson AG, Bax DE, Morgan AW, Emery P, Steer S, Hocking L, Reid DM, Wordsworth P, Harrison P, Thomson W, Barton A, Worthington J. Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. Ann Rheum Dis. 2009 doi:10.1136/ard.2009.109579.
   Google Scholar
• Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burtt NP, Gianniny L, Korman BD, Padyukov L, Kurreeman FA, Chang M, Catanese JJ, Ding B, Wong S, van der Helm-van Mil AH, Neale BM, Coblyn J, Cui J, Tak PP, Wolbink GJ, Crusius JB, van der Horst-Bruinsma IE, Criswell LA, Amos CI, Seldin MF, Kastner DL, Ardlie KG, Alfredsson L, Costenbader KH, Altshuler D, Huizinga TW, Shadick NA, Weinblatt ME, de Vries N, Worthington J, Seielstad M, Toes RE, Karlson EW, Begovich AB, Klareskog L, Gregersen PK, Daly MJ, Plenge RM. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet. 2008; 40 10: 1216–1223.
   PubMed Web of Science ®Google Scholar
• Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004; 22:307–328.
   PubMed Web of Science ®Google Scholar
• Iezzi G, Sonderegger I, Ampenberger F, Schmitz N, Marsland BJ, Kopf M. CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc Natl Acad Sci USA. 2009; 106 3: 876–881.
   PubMed Web of Science ®Google Scholar
• Jasny E, Eisenblatter M, Matz-Rensing K, Tenner-Racz K, Tenbusch M, Schrod A, Stahl-Hennig C, Moos V, Schneider T, Racz P, Uberla K, Kaup FJ, Ignatius R. IL-12-impaired and IL-12-secreting dendritic cells produce IL-23 upon CD154 restimulation. J Immunol. 2008; 180 10: 6629–6639.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003; 48 3: 719–727.
   PubMed Web of Science ®Google Scholar
• Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, Illei GG, Lipsky PE. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest. 2003; 112 10: 1506–1520.
   PubMed Web of Science ®Google Scholar
• Pree I, Wekerle T. New approaches to prevent transplant rejection: Co-stimulation blockers anti-CD40L and CTLA4Ig. Drug Discov Today Therapeut Strat. 2006; 3 1: 41–47.
   Google Scholar
• Langer F, Ingersoll SB, Amirkhosravi A, Meyer T, Siddiqui FA, Ahmad S, Walker JM, Amaya M, Desai H, Francis JL. The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost. 2005; 93 6: 1137–1146.
   PubMed Web of Science ®Google Scholar
• Mirabet M, Barrabes JA, Quiroga A, Garcia-Dorado D. Platelet pro-aggregatory effects of CD40L monoclonal antibody. Mol Immunol. 2008; 45 4: 937–944.
   PubMed Web of Science ®Google Scholar
• Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol. 2008; 141 4: 545–548.
   PubMed Web of Science ®Google Scholar
• Kasran A, Boon L, Wortel CH, Hogezand RA, Schreiber S, Goldin E, Boer M, Geboes K, Rutgeerts P, Ceuppens JL. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther. 2005; 22 2: 111–122.
   PubMed Web of Science ®Google Scholar
• Andreakos E, Rauchhaus U, Stavropoulos A, Endert G, Wendisch V, Benahmed AS, Giaglis S, Karras J, Lee S, Gaus H, Bennett CF, Williams RO, Sideras P, Panzner S. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum. 2009; 60 4: 994–1005.
   PubMed Web of Science ®Google Scholar
• Gao D, Wagner AH, Fankhaenel S, Stojanovic T, Schweyer S, Panzner S, Hecker M. CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut. 2005; 54 1: 70–77.
   PubMed Web of Science ®Google Scholar
• Kean LS, Gangappa S, Pearson TC, Larsen CP. Transplant tolerance in non-human primates: Progress, current challenges and unmet needs. Am J Transpl. 2006; 6 5 Pt 1: 884–893.
   PubMed Web of Science ®Google Scholar
• Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009; 229 1: 173–191.
   PubMed Web of Science ®Google Scholar
• Manku H, Graham DS, Vyse TJ. Association of the co-stimulator OX40L with systemic lupus erythematosus. J Mol Med. 2009; 87 3: 229–234.
   PubMed Web of Science ®Google Scholar
• Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, Chen SF, Hsieh SL, Nagata S, Ni J, Chen L. LIGHT, a TNF-like molecule, costimulates T-cell proliferation and is required for dendritic cell-mediated allogeneic T-cell response. J Immunol. 2000; 164 8: 4105–4110.
   PubMed Web of Science ®Google Scholar
• Duhen T, Pasero C, Mallet F, Barbarat B, Olive D, Costello RT. LIGHT costimulates CD40 triggering and induces immunoglobulin secretion; a novel key partner in T-cell-dependent B-cell terminal differentiation. Eur J Immunol. 2004; 34 12: 3534–3541.
   PubMed Web of Science ®Google Scholar
• Wan X, Zhang J, Luo H, Shi G, Kapnik E, Kim S, Kanakaraj P, Wu J. A TNF family member LIGHT transduces costimulatory signals into human T cells. J Immunol. 2002; 169 12: 6813–6821.
   PubMed Web of Science ®Google Scholar
• An MM, Fan KX, Zhang JD, Li HJ, Song SC, Liu BG, Gao PH, Zhou Q, Jiang YY. Lymphtoxin beta receptor-Ig ameliorates TNBS-induced colitis via blocking LIGHT/HVEM signaling. Pharmacol Res. 2005; 52 3: 234–244.
   PubMed Web of Science ®Google Scholar
• Brown GR, Lee EL, El-Hayek J, Kintner K, Luck C. IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T-cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease. J Immunol. 2005; 174 8: 4688–4695.
   PubMed Web of Science ®Google Scholar
• Fava RA, Notidis E, Hunt J, Szanya V, Ratcliffe N, Ngam-Ek A, De Fougerolles AR, Sprague A, Browning JL. A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol. 2003; 171 1: 115–126.
   PubMed Web of Science ®Google Scholar
• Gommerman JL, Giza K, Perper S, Sizing I, Ngam-Ek A, Nickerson-Nutter C, Browning JL. A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT. J Clin Invest. 2003; 112 5: 755–767.
   PubMed Web of Science ®Google Scholar
• Pierer M, Schulz A, Rossol M, Kendzia E, Kyburz D, Haentzschel H, Baerwald C, Wagner U. Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model. J Immunol. 2009; 182 5: 3139–3145.
   PubMed Web of Science ®Google Scholar
• Wang J, Anders RA, Wang Y, Turner JR, Abraham C, Pfeffer K, Fu YX. The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J Immunol. 2005; 174 12: 8173–8182.
   PubMed Web of Science ®Google Scholar
• Fan K, Wang H, Wei H, Zhou Q, Kou G, Hou S, Qian W, Dai J, Li B, Zhang Y, Zhu T, Guo Y. Blockade of LIGHT/HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance. Transplantation. 2007; 84 6: 746–754.
   PubMed Web of Science ®Google Scholar
• Scheu S, Alferink J, Potzel T, Barchet W, Kalinke U, Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T-cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med. 2002; 195 12: 1613–1624.
   PubMed Web of Science ®Google Scholar